Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.
about
Biomedical and clinical promises of human pluripotent stem cells for neurological disordersRecent Progress in Stem Cell Therapy for Diabetic NephropathyInduced Pluripotent Stem Cell as a New Source for Cancer ImmunotherapyThe Application of Human iPSCs in Neurological Diseases: From Bench to BedsideModeling Kidney Disease with iPS CellsStem cell technology for tendon regeneration: current status, challenges, and future research directionsRegenerative medicine: Current therapies and future directionsThe immune response of stem cells in subretinal transplantationMesenchymal and induced pluripotent stem cells: general insights and clinical perspectivesThe Possible Future Roles for iPSC-Derived Therapy for Autoimmune DiseasesThe Dark Side of the Force - Constraints and Complications of Cell Therapies for StrokeClinical implications of basic science discoveries: induced pluripotent stem cell therapy in transplantation--a potential role for immunologic toleranceStem cells in retinal regeneration: past, present and futureInduced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screeningHuman embryonic stem cell-derived oligodendrocytes: protocols and perspectivesInduction of pluripotency by defined factorsImmunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectivesThe potential for immunogenicity of autologous induced pluripotent stem cell-derived therapiesConcise review: making and using clinically compliant pluripotent stem cell linesStem cell imaging: from bench to bedsideConsiderations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytesInduced pluripotent stem cell (iPSCs) and their application in immunotherapyModeling AEC-New approaches to study rare genetic disordersPluripotent stem cells in regenerative medicine: challenges and recent progressCan pluripotent stem cells be used in cell-based therapy?The immunogenicity of cells derived from induced pluripotent stem cellsGene therapy on the moveInduced pluripotent stem cells in hematology: current and future applicationsModelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroidsStem Cell Therapy: A Prospective Treatment for Alzheimer's DiseasePotential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD)Present and future challenges of induced pluripotent stem cellsBanking on iPSC--is it doable and is it worthwhileEfficient reprogramming of naïve-like induced pluripotent stem cells from porcine adipose-derived stem cells with a feeder-independent and serum-free systemControlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantationToward pluripotency by reprogramming: mechanisms and applicationThe Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell TransplantationTechnology advancement for integrative stem cell analysesPerspectives of gene combinations in phenotype presentationBone Tissue Engineering: Past-Present-Future.
P2860
Q21284798-F2C2E679-7E56-404C-823A-41A1A0E75B33Q26740433-DEB4AA07-12FB-40DE-B728-641A38F4FDC0Q26750579-A5855992-DA30-44E9-A2FE-D9D0AFC550C4Q26765876-17F95719-C4D6-4C27-BE0C-B089198E334DQ26770384-20C834A4-F595-43CD-ABD4-CDA56D090558Q26771642-0A3FAB77-14A3-42B6-8C44-A3BF6EFDC942Q26776380-B600E1B4-2654-4B4F-A2A4-1E74506DBCFFQ26781292-44D6F72F-327C-4603-A33D-C7D625CFE158Q26785623-C1B169B1-F8E2-4CD5-83CE-FADE00C44686Q26799472-85456BA4-FD36-4ED4-8954-26B2FCACC257Q26800181-39F67374-D9C7-437A-A987-4142E5B200ACQ26824632-9859917E-B47A-401C-AE3B-4C3DF5C09A29Q26828014-1D76A938-B2FD-4D23-95D5-05D9FC1C69FEQ26828408-5C687B3A-2286-489E-A791-42D85E50D099Q26829414-582512C0-C7B0-4FC7-B03E-274D4FC9E277Q26830425-AD140BD6-B125-457E-95B6-8717AD642136Q26849530-B1E811DC-CF6B-40B9-99D2-0B80B9670C2BQ26851666-9FD3D45F-6AA4-4720-97BC-0DD2EFBE8740Q26852128-AD3433AD-5E94-405F-B6A4-25B8B048A3DEQ26861615-C0B7DBA3-DC8F-407C-A209-479E366C55A0Q26865173-42918872-E113-4DA1-9229-A8CC6C291A66Q26996540-2BA9E604-640C-4B53-9CD6-81D23715CEBAQ26996543-4347FF1F-8470-40DE-84A0-6E8C1A23630CQ26999292-10BF5C43-6437-4866-A20F-3FF7573B0596Q27002327-9961C918-EAAF-465C-AB09-3C31494D1549Q27003999-B5B54B05-1808-44FE-B2F6-F7BD0893FCD4Q27007012-EF27999C-3C32-4658-849E-5FB4858D2B87Q27016090-26F50288-B36C-4B10-921D-2D1B5FCFFDD6Q27319887-47CCB18C-1039-4933-BE8C-F70C95F0685CQ28069506-BC9F5863-3D58-4D74-8517-B786F7B8F572Q28077285-DDB7BBA4-9180-409A-AED0-140444673AB2Q28082747-6AA9A224-893A-4FAA-BC84-3F20645DA308Q28254023-A6919715-C62F-4DEA-9284-6B70BA9A9C7FQ28538854-79F5E1B3-D7A9-4890-B5D5-AA43F943EE33Q28543575-E8E9EC30-E8EE-4CA2-BE57-4FCFA1A3EC50Q28833688-12390B57-92C6-4727-A82E-CDFFD9BC2F18Q28973616-BC6E3089-72D1-4AB5-9757-4E39210DADFAQ30397631-21CCD1C3-5975-44B3-B3E6-CA59A7EA6F24Q30450809-497AD148-15FA-4451-A52B-098398454736Q33363234-DAE9F280-D823-4E7E-ABA5-CA8C68F00710
P2860
Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@ast
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@en
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@nl
type
label
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@ast
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@en
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@nl
prefLabel
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@ast
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@en
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@nl
P2093
P2860
P356
P1433
P1476
Negligible immunogenicity of t ...... otent or embryonic stem cells.
@en
P2093
Akemi Shimada
Akira Nifuji
Hisashi Ideno
Masahiro Uda
Masumi Abe
Mayumi Sugiura
Miki Nakamura
Misato Sunayama
Ryoko Araki
Shunsuke Ando
P2860
P2888
P304
P356
10.1038/NATURE11807
P407
P577
2013-01-09T00:00:00Z
P5875
P6179
1012678761